Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice.

Cortellini A, Cannita K, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Dal Mas A, Calvisi G, Giordano AV, Vicentini V, Vicentini R, Felicioni L, Marchetti A, Buttitta F, Russo A, Ficorella C.

Onco Targets Ther. 2019 Mar 25;12:2159-2170. doi: 10.2147/OTT.S194745. eCollection 2019.

2.

Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation.

Napoleoni L, Cortellini A, Cannita K, Parisi A, Dal Mas A, Calvisi G, Venditti O, Baldi PL, Cocciolone V, Ricci A, Ficorella C.

Bioengineering (Basel). 2019 Jan 22;6(1). pii: E11. doi: 10.3390/bioengineering6010011.

3.

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A 'hypothesis-generator' study from clinical practice.

Cortellini A, Cocciolone V, Irelli A, Pavese F, Sidoni T, Parisi A, Lanfiuti Baldi P, Venditti O, D'Orazio C, Bonfili P, Franzese P, Zugaro L, Verna L, Porzio G, Santini D, Cannita K, Ficorella C.

Oncol Lett. 2018 Dec;16(6):7195-7203. doi: 10.3892/ol.2018.9561. Epub 2018 Oct 10.

4.

Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.

Cocciolone V, Cannita K, Tessitore A, Mastroiaco V, Rinaldi L, Paradisi S, Irelli A, Baldi PL, Sidoni T, Ricevuto E, Dal Mas A, Calvisi G, Coletti G, Ciccozzi A, Pizzorno L, Resta V, Bafile A, Alesse E, Ficorella C.

Oncotarget. 2018 Jun 8;9(44):27380-27396. doi: 10.18632/oncotarget.25270. eCollection 2018 Jun 8.

5.

Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.

Cortellini A, Cannita K, Parisi A, Venditti O, Lanfiuti Baldi P, De Berardis B, Vicentini R, Vicentini V, Verna L, Porzio G, Ficorella C.

Oncol Rep. 2018 Aug;40(2):803-812. doi: 10.3892/or.2018.6475. Epub 2018 Jun 6.

PMID:
29901103
6.

Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.

Cocciolone V, Cannita K, Calandrella ML, Ricevuto E, Baldi PL, Sidoni T, Irelli A, Paradisi S, Pizzorno L, Resta V, Bafile A, Alesse E, Tessitore A, Ficorella C.

Oncotarget. 2017 Jun 16;8(42):72031-72043. doi: 10.18632/oncotarget.18526. eCollection 2017 Sep 22.

7.

New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.

Cannita K, Paradisi S, Cocciolone V, Bafile A, Rinaldi L, Irelli A, Lanfiuti Baldi P, Zugaro L, Manetta R, Alesse E, Ricevuto E, Ficorella C.

Cancer Med. 2016 Sep;5(9):2232-9. doi: 10.1002/cam4.803. Epub 2016 Jul 15.

8.

Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.

Irelli A, Cocciolone V, Cannita K, Zugaro L, Di Staso M, Lanfiuti Baldi P, Paradisi S, Sidoni T, Ricevuto E, Ficorella C.

Bone. 2016 Jun;87:169-75. doi: 10.1016/j.bone.2016.04.006. Epub 2016 Apr 26. Review.

PMID:
27091227
9.

Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.

Ficorella C, Bruera G, Cannita K, Porzio G, Baldi PL, Tinari N, Natoli C, Ricevuto E.

Clin Colorectal Cancer. 2012 Dec;11(4):229-37. doi: 10.1016/j.clcc.2012.05.001. Epub 2012 Jun 12. Review.

PMID:
22694897
10.

Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.

Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E.

Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27.

PMID:
22206922
11.

Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.

Tudini M, Palluzzi E, Cannita K, Mancini M, Santomaggio A, Bruera G, Baldi PL, Pelliccione M, Ricevuto E, Ficorella C.

Oncol Rep. 2012 Feb;27(2):423-32. doi: 10.3892/or.2011.1517. Epub 2011 Oct 21.

PMID:
22020810
12.

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E.

BMC Cancer. 2010 Oct 19;10:567. doi: 10.1186/1471-2407-10-567.

13.

Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer.

Rispoli AI, Morelli MF, Ricevuto E, Cannita K, Santomaggio A, Mancini M, Tudini M, Cianci G, Porzio G, Lanfiuti Baldi P, Di Rocco CZ, Tinari N, Iacobelli S, Marchetti P, Ficorella C.

Breast J. 2008 Jan-Feb;14(1):116-7. Epub 2007 Dec 13. No abstract available.

PMID:
18086273

Supplemental Content

Loading ...
Support Center